Bedrijfsoverzicht
DexCom, Inc. is a medical device company dedicated to the design, development, and commercialization of continuous glucose monitoring (CGM) systems, which are essential tools for managing diabetes and metabolic health in both the United States and international markets. The organization operates within the Healthcare sector, specifically inside the Medical Devices industry, positioning it as a critical player in the intersection of technology and patient care. The company demonstrates significant scale with a market capitalization of $24.97B and an annual revenue of $4.66B, supported by a workforce of 11,000 employees. These valuation and revenue figures indicate that DexCom has established itself as a major entity with substantial market presence, reflecting high investor confidence in its product pipeline and operational capabilities within the competitive medical device landscape.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $4.66B, generating net income of $836.30M and an EBITDA of $1.16B. The substantial gap between the total revenue and net income reveals a cost structure where operating expenses, including research, development, and cost of goods sold, consume a significant portion of top-line growth before reaching the bottom line. Free cash flow stands at $719.54M, which provides the company with strong financial flexibility to fund ongoing innovation, manage capital expenditures, or pursue strategic acquisitions without relying heavily on external financing. Profitability is analyzed through three key margins: a gross margin of 60.1% indicates efficient production and pricing power, an operating margin of 25.6% reflects effective cost control and operational leverage, and a profit margin of 17.9% demonstrates the company's ability to convert revenue into actual shareholder profit. Regarding balance sheet strength, the company holds $2.00B in cash against $1.40B in debt, resulting in a debt-to-equity ratio of 50.85%, which suggests a moderately leveraged position rather than a purely conservative one. Liquidity is further supported by a current ratio of 1.88, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities comfortably. Management effectiveness is highlighted by a return on equity of 34.5% and a return on assets of 8.9%, metrics that reveal how efficiently the company utilizes shareholder capital and total assets to generate returns.
Waarderingsbeoordeling
Valuation multiples for DexCom show a trailing P/E ratio of 30.63 compared to a forward P/E of 21.39, implying that the market expects earnings growth that will significantly lower the valuation multiple over the next year. The price-to-book ratio stands at 8.97, indicating that the market values the company at a substantial premium over its book value, likely due to the intangible nature of its intellectual property and growth prospects. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 5.36 and an EV/EBITDA of 20.66, suggesting that investors are pricing in high growth potential relative to sales and earnings generation. Price momentum is observed within a 52-week trading range bounded by a high of $89.98 and a low of $54.11, where the current price sits approximately 47.6% below the 52-week high. The stock exhibits a beta of 1.56, meaning it tends to be more volatile than the broader market, amplifying price swings in response to general market movements or sector-specific developments.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 13.1% year-over-year paired with an impressive earnings growth rate of 78.0% year-over-year. The fact that earnings are growing significantly faster than revenue implies that the company is benefiting from operating leverage, likely through scaling production efficiencies or favorable cost dynamics as revenue expands. As a non-dividend payer, DexCom reports a dividend yield of N/A and a payout ratio of 0.0%, indicating a strategy of reinvesting all earnings into research and development, market expansion, or debt reduction rather than distributing cash to shareholders. The overall growth and income profile presents a classic growth stock pattern where capital retention fuels future expansion, supported by robust profitability and a balance sheet capable of sustaining rapid scaling efforts.